N. Lea

发表

BCR signals target p27Kip1 and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells

E. Lam, J. Glassford, L. Banerji, 2001, Oncogene.

Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry

E. Marcotte, D. Boutz, G. Mufti, 2012, Molecular systems biology.

MicroRNA expression profiling of high and low risk MDS

G. Mufti, N. Lea, B. Czepulkowski, 2009 .

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

G. Mufti, N. Lea, U. Germing, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways

G. Mufti, M. Arno, N. Lea, 2001, The Journal of Immunology.

High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells.

G. Mufti, N. Lea, S. Orr, 2003, Journal of biochemical and biophysical methods.

BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression*

E. Lam, E. Lam, C. Rivas, 2001, The Journal of Biological Chemistry.

Cyclin D2 controls B cell progenitor numbers

E. Lam, G. Mufti, J. Glassford, 2003, Journal of leukocyte biology.

Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten‐eleven translocation 2 mutations in budd‐chiari syndrome and their impact on thrombotic complications post Liver Transplantation

G. Mufti, N. Lea, M. Heneghan, 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto‐splenomesenteric venous thrombosis

G. Mufti, N. Heaton, N. Lea, 2010, Alimentary pharmacology & therapeutics.

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

G. Mufti, P. Antunović, M. Arno, 2006, Leukemia.

Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia

M. Arno, N. Lea, N. Westwood, 2006, Leukemia.

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

F. Solé, G. Mufti, J. Cervera, 2020, Leukemia.

Genetic instability as an area of potential therapeutic intervention

G. Mufti, N. Lea, T. Gaymes, 2007 .

AKT1 (E17K) Mutation in Pancreatic Cancer

G. Mufti, N. Lea, H. Kocher, 2008, Technology in cancer research & treatment.

The JAK2 V617F mutation is rare in RARS but common in RARS-T

G. Mufti, J. Cervera, N. Lea, 2006, Leukemia.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells

G. Mufti, N. Lea, S. Best, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen is Shaped by Persistence of Recipient CD8 T Cells. BIOLOGY OF BLOOD AND MARROW

G. Mufti, N. Lea, S. Best, 2017 .

p27Kip1 and p130 Cooperate To Regulate Hematopoietic Cell Proliferation In Vivo

E. Lam, K. Naresh, R. Watson, 2006, Molecular and Cellular Biology.

The Scope of Viral Vectors for the Transduction of Haemopoietic Cells.

G. Mufti, N. Lea, Ghulam J. Mufti, 1998, Hematology.

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.

G. Mufti, S. Jackson, D. Mclornan, 2019, The Lancet. Haematology.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Soma Das, G. Mufti, Xingmin Feng, 2018, Blood advances.

Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

G. Mufti, N. Lea, T. Gaymes, 2010 .

Prevalence and prognostic signiﬁcance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

G. Mufti, N. Lea, U. Germing, 2007 .

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

G. Mufti, N. Lea, T. Gaymes, 2013 .

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

G. Mufti, F. Farzaneh, N. Lea, 2009, Haematologica.

Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.

G. Mufti, A. Douiri, N. Lea, 2016, The Journal of infection.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Soma Das, G. Mufti, Xingmin Feng, 2018, Blood advances.

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

G. Mufti, N. Lea, T. Seidl, 2013, Haematologica.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

G. Mufti, J. Maciejewski, N. Lea, 2010, Blood.

Epigenetics of human T cells during the G0-->G1 transition.

A. Bhinge, G. Mufti, N. Lea, 2009, Genome research.

syndromes single-nucleotide polymorphism analysis in low-risk myelodysplastic Prevalence and prognostic significance of allelic imbalance by

G. Mufti, N. Lea, N. Donaldson, 2013 .

nucleotide polymorphism analysis in low risk myelodysplastic syndromes Prevalence and prognostic significance of allelic imbalance by single

G. Mufti, N. Lea, U. Germing, 2013 .

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

G. Mufti, N. Lea, U. Germing, 2007, Blood.

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells

J. Fitzgibbon, V. Rajeeve, P. Cutillas, 2017, Leukemia.

Effect of costimulation and the microenvironment on antigen presentation by leukemic cells.

G. Mufti, F. Farzaneh, N. Lea, 1999, Blood.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

G. Mufti, N. Lea, B. Czepulkowski, 2013, British journal of haematology.

GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML

J. Fitzgibbon, T. Vulliamy, J. Cavenagh, 2018, Leukemia.

Commitment Point during G0→G1 That Controls Entry into the Cell Cycle

E. Lam, K. Stoeber, G. Mufti, 2003, Molecular and Cellular Biology.

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2-Mutated MDS/AML

J. Fitzgibbon, T. Vulliamy, J. Cavenagh, 2016 .

Title: Mixed T-Cell Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab- Containing Regimen is Shaped by Persistence of Recipient CD8 T Cells

G. Mufti, N. Lea, S. Best, 2016 .

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

G. Mufti, N. Lea, Z. Lim, 2011, Leukemia research.

Initial Studies to Identify Chromatin/nuclear Matrix-bound Proteins in G 0 and G 1 ................. 3 Effect of Detergent Removal on Detection of Proteins Using the Ltq-orbitrap Mass

E. Marcotte, D. Boutz, G. Mufti, 2012 .

Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?

G. Mufti, N. Lea, M. Pla, 2007, Cancer research.

Myeloid Leukemia? Repair: A Model for Genomic Instability with Progression in Reactive Oxygen Species, DNA Damage, and Error-Prone

G. Mufti, N. Lea, M. Pla, 2007 .

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

G. Mufti, N. Heaton, N. Lea, 2005, Gastroenterology.

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.

J. Fitzgibbon, V. Rajeeve, P. Cutillas, 2017, Leukemia.

Cell Proliferation and Cell Death

Shaun Thomas, N. Lea, Nicholas Lea, 2002 .

JAK V617F missense mutation is absent in pancreatic cancer

G. Mufti, N. Lea, H. Kocher, 2007, Gut.

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

C. Eberlein, L. Bullinger, K. Döhner, 2014 .

after Stem Using

G. Mufti, N. Lea, S. Best, 2016 .

Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations

G. Mufti, N. Lea, M. Heneghan, 2009 .

Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.

G. Mufti, A. Douiri, N. Lea, 2016, The Journal of infection.